~ Buy the BRENZAVVY (bexagliflozin) Drug Profile, 2024 PDF Report in the Report Store ~

BRENZAVVY Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Brenzavvy, and when can generic versions of Brenzavvy launch?

Brenzavvy is a drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this drug.

This drug has seventy-one patent family members in thirty-two countries.

The generic ingredient in BRENZAVVY is bexagliflozin. Two suppliers are listed for this compound. Additional details are available on the bexagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Brenzavvy

Brenzavvy will be eligible for patent challenges on January 20, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 20, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for BRENZAVVY?
What are the global sales for BRENZAVVY?
What is Average Wholesale Price for BRENZAVVY?

Summary for BRENZAVVY

International Patents:	71
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	54
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRENZAVVY
What excipients (inactive ingredients) are in BRENZAVVY?	BRENZAVVY excipients list
DailyMed Link:	BRENZAVVY at DailyMed

Drug patent expirations by year for BRENZAVVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRENZAVVY

Generic Entry Date for BRENZAVVY^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 214373 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BRENZAVVY

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

US Patents and Regulatory Information for BRENZAVVY

BRENZAVVY is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BRENZAVVY is ⤷ Sign Up.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BRENZAVVY

Crystalline form of benzylbenzene SGLT2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Benzylbenzene derivatives and methods of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Crystalline form of benzylbenzene SGLT2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting BRENZAVVY

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for BRENZAVVY

See the table below for patents covering BRENZAVVY around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Argentina	110796	DERIVADOS DE BENCILBENCENO	⤷ Sign Up
Brazil	PI0815708	COMPOSTO, ÉSTER DE PRÓ-DROGA, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA TRATAR UMA DOENÇA OU CONDIÇÃO.	⤷ Sign Up
Croatia	P20180127		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration